Go on the Offensive Against Colorectal Cancer

The FDA granted an accelerated approval to zanidatamab-hrii for previously treated, unresectable or metastatic HER2-positve biliary tract cancer.

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Developing a strong working relationships and understanding the physical and emotional demands of the oncology specialty are some ways nurses can address burnout, an expert said.

In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.

The fast track status from the FDA is supported by findings from a phase 1 trial in glioblastoma, which demonstrated the overall survival benefit from DOC1021.

The overall survival rate in patients with advanced biliary tract cancer treated with durvalumab plus chemotherapy was nearly double the rate of those treated with chemotherapy alone.